Analysts Offer Insights on Healthcare Companies: Endo International (NASDAQ: ENDP) and ProQR (NASDAQ: PRQR)

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Endo International (NASDAQ: ENDP) and ProQR (NASDAQ: PRQR) with bullish sentiments.

Endo International (NASDAQ: ENDP)

JMP Securities analyst Donald Ellis reiterated a Buy rating on Endo International (NASDAQ: ENDP) today. The company’s shares opened today at $17.11, close to its 52-week low of $12.56.

According to TipRanks.com, Ellis is a 4-star analyst with an average return of 25.8% and a 80.0% success rate. Ellis covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Pacira Pharmaceuticals, and Horizon Pharma Inc.

Currently, the analyst consensus on Endo International is Moderate Buy and the average price target is $26, representing a 52.0% upside.

In a report issued on November 11, Mizuho Securities also reiterated a Buy rating on the stock with a $25 price target.
ProQR (NASDAQ: PRQR)

In a report released today, Liisa Bayko from JMP Securities reiterated a Buy rating on ProQR (NASDAQ: PRQR). The company’s shares opened today at $4.70, close to its 52-week low of $3.48.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 5.6% and a 54.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Anthera Pharmaceuticals, and Conatus Pharmaceuticals.

Currently, the analyst consensus on ProQR is Moderate Buy and the average price target is $25, representing a 431.9% upside.

In a report issued on November 14, Leerink Swann also reiterated a Buy rating on the stock with a $10 price target.